tirzepatide diabetic retinopathy Dual GIP/GLP-1 Drug Linked to Reduced Incidence Tirzepatide may protect against diabetic

FOXO4-DRI enters senescent cells and competitively binds to p53 through its modified peptide sequence, displacing endogenous FOXO4 and freeing p53 to activate cell death pathways including BAX and PUMA

One of the most common questions we hear is whether it is safe to transition between different types of medications, specifically from tirzepatide to semaglutide

BPC-157 amplifies growth hormone activity not by increasing hormone levels but by upregulating the receptors that respond to it

For weight management, NICE (TA875) recommends semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m or greater (or 32.5 kg/m or greater for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) who have at least one weight-related comorbidity